Antares Pharma, Inc. (ATRS)

[richdag]

Oppenheimer maintains Outperform, lowers target slightly to $3.00 from $3.20.

December 15, 2011
07:56 EDT AIS, BPAX
theflyonthewall.com: Antares decline on LibiGel data overdone, says Oppenheimer
After Antares' (AIS) partner, BioSante (BPAX), announced disappointing efficacy data for female sexual dysfunction treatment LibiGel, Oppenheimer thinks that the placebo effect shown in the trial will be difficult to overcome. The firm lowered its target on Antares to $3 from $3.20 but maintains an Outperform rating. :theflyonthewall.com